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Cardiovascular risk is significantly lower in normally cycling
women compared with men. This difference is abolished
after menopause, suggesting a link with sex steroid hor-
mones. Early studies on cardiac endocrine function dis-
closed higher natriuretic peptide concentrations in women
than in men, suggesting the hypothesis that female sex
steroid hormones could directly stimulate cardiomyocyte
hormone production and secretion (1). Kuroski de Bold (2)
hypothesized that an improved cardiovascular risk profile in
cycling women could be associated with some estrogen
stimulatory effect on cardiac endocrine function. Indeed,
cardiac natriuretic peptides exert several protective actions on
the heart and vessels, including: 1) vasodilatation; 2) promotion
of diuresis/natriuresis; and 3) inhibition of hypertrophy, fibro-
sis, and apoptosis either directly or via inhibition of the
sympathetic and renin-angiotensin-aldosterone systems, as
well as the release or action of endothelin and vasopressin (1).
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More recently, 3 large population-based studies have indi-
cated that male sex steroid hormones might modulate cardiac
endocrine function too (3–5). These studies demonstrated a
significant inverse association between the circulating levels of
B-type natriuretic peptide (BNP) or N-terminal fragment of
pro-B-type natriuretic peptide (NT-proBNP) and male sex
steroid hormones (i.e., total and free testosterone) in both sexes
(3–5), whereas the association with estradiol was found to be
weak or not significant at all (3,4). Furthermore, these studies
reported that levels of sex hormone–binding globulin (SHBG)
are positively associated with NT-proBNP levels in both male and
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(5). Testosterone and estradiol circulate in the bloodstream mostly
bound to SHBG, with levels that directly influence bioavailability
of sex hormones; only a small fraction of total steroid concentra-
tion is unbound or “free” (1% to 5%) and biologically active (i.e.,
able to enter a cell and activate its receptors).
Lam et al. (5), in this issue of the Journal, evaluate plasma
NT-proBNP, total testosterone, and SHBG concentrations in
4,056 adult men and women from the Framingham Heart
Study Third-Generation Cohort; estradiol was not measured.
They found lower NT-proBNP plasma levels in men than in
age-matched women and higher NT-proBNP levels in women
receiving hormonal contraceptives than in women who were
not (5). Moreover, serum free (non–protein-bound) testoster-
one was positively and serum SHBG was negatively related to
circulating NT-proBNP levels (5). The investigators sug-
gested the hypothesis that androgens suppress NT-proBNP
and that differences in free testosterone levels may largely
explain the sex- and hormone-related differences in circu-
lating levels of natriuretic peptides. They concluded that
lower levels of circulating androgens and the potentiating
effect of exogenous female hormone therapy contribute to
the higher circulating NT-proBNP levels in women.
These findings (3–5) need detailed consideration. Data
concerning variations in BNP and NT-proBNP values from
birth to puberty are poor; indeed, only 2 recent studies
reported reference BNP/NT-proBNP values for infants and
pre-puberal boys and girls (6,7). In cycling women, estradiol
concentrations are greatly variable during the cycle (up to
50-fold). For accurate physiological and clinical studies,
blood samples should be collected at the same (estrogenic or
luteal) phase of the cycle in all women, and multiple
sampling throughout the same cycle (or even repeated on
more than 1 cycle) should be considered necessary. Further-
more, environmental, social, economical, and ethnic differ-
ences all play an important role in determining the age of
onset of both puberty and menopause, greatly increasing the
between-subject variability in female sex steroid levels.
Because of great biological variability in estradiol concen-
trations, it is not surprising to find weak or even absent
association between estradiol and BNP/NT-proBNP levels in
large population-based studies (3,4).
On the other hand, a significant and positive association
between SHBG and cardiac natriuretic peptide levels (3–5)
may require an alternative interpretation to the one sug-
gested by Lam et al. (5), indicating a relevant influence
(instead of no effect) of estrogenic status on BNP/NT-
proBNP levels. Indeed, sex steroid hormones regulate the
liver production of SHBG in an opposite way: estrogens
show a powerful stimulatory action, whereas androgens have
an inhibitory one (8). Accordingly, increased SHBG levels
should indicate a relative estrogenic activation with respect
to the androgenic system (8). Plasma SHBG levels are low
at birth, increase gradually, and peak just before puberty,
when the levels decrease in parallel with the increase in
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levels in women are on average twice as high as those in men
(9). In men, serum SHBG levels gradually increase with age
(in the ninth decade, the levels are double those in the third
decade) (10), whereas in women, the SHBG levels dip
transiently after menopause, increasing thereafter (11).
Actually, causal-effect relationships can be better demon-
strated by means of experimental studies, using animal and
clinical models, rather than population studies. Unfortunately,
there have been only a few studies in animal models specifically
designed to investigate the influence of sex steroid hormones
on cardiac endocrine function, all regarding atrial natriuretic
peptide (ANP) but not BNP (12). In rats, both ovariectomy
and orchiectomy decreased atrial ANP mRNA transcripts in
vivo, whereas pretreatment of Wistar female rats with estradiol
and progesterone for 7 days increased atrial ANP gene expres-
sion (13). It was observed in another study that plasma ANP
concentrations and atrial stores were increased by orchiectomy
in male rats, with testosterone replacement decreasing plasma
ANP concentrations but not atrial stores (14). Other studies
have shown that testosterone stimulates synthesis and secretion
of both ventricular and atrial ANP in newborn rat atrial
cultured myocytes (15,16).
Some clinical studies have demonstrated that estrogens,
administered for contraception in pre-menopausal women
(5) or as hormone replacement therapy in post-menopausal
women (17,18), increase the circulating levels of BNP and
NT-proBNP. Moreover, androgen receptor blockade, and
to a lesser extent, androgen suppression cause an increase in
NT-proBNP levels in men with prostate cancer (19).
On the whole, data in the literature have suggested
antagonist effects of androgens (inhibitory) and estrogens
(excitatory) on cardiac endocrine function, but we still lack
information on how this balance exerts its influence in either
gender throughout the human life span. The hypothesis that
gonadal function may regulate cardiac endocrine function,
thus contributing to the gender difference in cardiovascular
risk, needs further experimental effort to show 1) the
conclusive demonstration that sex steroids are able to affect
(increase or decrease) the production/secretion of BNP from
mammalian/human cardiomyocytes both in cell cultures and
in vivo (12); 2) the knowledge of the exact mechanisms and
of the evolution of male/female steroid balanced action on
cardiac endocrine function, from childhood to puberty,
maturity, and old age; and 3) the evaluation of the relative
impact/interplay of male and female sex hormones, SHBG,
and cardiac natriuretic peptides, with respect to their pre-
dictive value for cardiovascular events in large cohorts, such
as the Framingham one.
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